pharma · Pulmonary Hypertension Associated with Interstitial Lung Disease · Pulmonary Arterial Hypertension
Insmed Incorporated
Insmed Limited
Insmed is a pharma organization headquartered in GB. Primary therapeutic focus areas include Pulmonary Hypertension Associated with Interstitial Lung Disease, Pulmonary Arterial Hypertension, Chronic Rhinosinusitis witho
Bridgewater Township, USA HQ
1,666 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Bridgewater Township, USA
- Employees
- 1,666
- Programs
- 7
- Drugs
- 18
- Patents
- 0
The BiRCh Study
Phase 2 · small molecule · Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
The BiRCh Study for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) is a Phase 2 program (small_molecule) at Insmed Limited with 1 ClinicalTrials.gov record(s).
Internal code The BiRCh Study
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Insmed Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
- Status
- active
- Trials
- 1